Compare Boston Beer Company Inc (SAM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Sana Biotechnology Inc — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Boston Beer Company Inc is far larger — about 2.2× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SAM | SANA | |
|---|---|---|
Market Cap | $1.88B | $873.84M |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $5.92 |
52-Week Low | $161.08 | $2.68 |
Enterprise Value | $1.75B | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $170.98, down 4.37% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, though 2026 projections show potential challenges with expected revenue decline and negative margins. Recent earnings show a mix of beats and misses, with Q2 2026 results pending.
The stock presents a cautious opportunity with analyst consensus target of $204.33 suggesting 19% upside, but faces headwinds from declining volumes, competitive pressure in hard seltzer market, and negative FY26 EPS growth projections. Institutional sentiment leans neutral with 74% hold ratings, reflecting balanced risk-reward amid evolving consumer beverage preferences.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
